Phase II multicenter study of induction chemotherapy followed by concurrent efaproxiral (RSR13) and thoracic radiotherapy for patients with locally advanced non-small-cell lung cancer

Journal of Clinical Oncology

Volumn 23, Issue 25, 2005, Pages 5918-5928

  Choy, Hak ^a   Nabid, Abdenour ^a   Stea, Baldassarre ^a   Scott, Charles ^a   Roa, Wilson ^a   Kleinberg, Larry ^a   Ayoub, Joseph ^a   Smith, Colum ^a   Souhami, Luis ^a   Hamburg, Solomon ^a   Spanos, William ^a   Kreisman, Harvey ^a   Boyd, Adam P ^a   Cagnoni, Pablo J ^a   Curran, Walter J ^a  

^a JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; EFAPROXIRAL; PACLITAXEL; ANILINE DERIVATIVE; ANTINEOPLASTIC AGENT; PROPIONIC ACID DERIVATIVE; RADIOSENSITIZING AGENT;

ADD ON THERAPY; ADULT; ADVANCED CANCER; AGED; ANEMIA; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CREATININE BLOOD LEVEL; DIARRHEA; DIZZINESS; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE SEQUENCE; DRUG RESPONSE; DYSPNEA; ESOPHAGITIS; FATIGUE; FEMALE; FEVER; HEADACHE; HUMAN; HYPERGLYCEMIA; HYPERSENSITIVITY; HYPOTENSION; HYPOXEMIA; HYPOXIA; LIVER TOXICITY; LOADING DRUG DOSE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; PHASE 2 CLINICAL TRIAL; PHOTON THERAPY; PRIORITY JOURNAL; RADIATION DERMATITIS; RADIATION PNEUMONIA; RADIOSENSITIVITY; SENSORY NEUROPATHY; SIDE EFFECT; TREATMENT OUTCOME; TREATMENT PLANNING; VOMITING; INTRAVENOUS DRUG ADMINISTRATION; LUNG TUMOR; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOLOGY; SURVIVAL;

ADULT; AGED; ANILINE COMPOUNDS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; COMBINED MODALITY THERAPY; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PACLITAXEL; PROPIONIC ACIDS; RADIATION-SENSITIZING AGENTS; SURVIVAL ANALYSIS;

EID: 24944451546     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.08.011     Document Type: Article

References (40)

1. Jemal A, Thomas A, Murray T, et al: Cancer statistics, 2002. CA Cancer J Clin 52:23-47, 2002
2. Detterbeck FC: Diagnosis and treatment of lung cancer, in An Evidence-Based Guide for the Practicing Physician. Philadelphia, PA, WB Saunders, 2000
3. Bulzebruck H, Bopp R, Drings P, et al: New aspects in the staging of lung cancer: Prospective validation of the International Union Against Cancer TNM classification. Cancer 70: 1102-1110, 1992
4. Govindan R: Management of patients with non-small cell lung cancer and poor performance status. Curr Treat Options Oncol 4:55-59, 2003
5. Dillman RO, Herndon J, Seagren SL, et al: Improved survival in stage III non-small cell lung cancer: Seven-year follow-up of Cancer and Leukemia group B (CALGB) 8433 trial. J Natl Cancer Inst 88:1210-1215, 1996
6. Sause W, Kolesar P, Taylor SI, et al: Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. Chest 117:358-364, 2000
7. Le Chevalier T, Arriagada R, Quoix E, et al: Radiotherapy alone vs. combined chemotherapy and radiotherapy in non-resectable non-small cell lung cancer: First analysis of a randomized trial in 353 patients. J Natl Cancer Inst 83:417-423, 1991
8. Schaake-Koning C, van den Bogaert W, Dalesio O, et al: Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med 326:524-530, 1992
9. Furuse K, Fukuoka M, Takada Y, et al: Phase III study of concurrent vs sequential thoracic radiotherapy (RT) in combination with mitomycin (M), vindesine (V), and cisplatin (P) in unresectable stage III non-small cell lung cancer (NSCLC): Five-year median follow-up results (abstract). Proc Am Soc Clin Oncol 18:458a, 1999
10. Curran W, Scott C, Langer C, et al: Phase III comparison of sequential vs concurrent chemoradiation for patients (Pts) with unresected stage III non-small cell lung cancer (NSCLC): Initial report of Radiation Therapy Oncology Group (RTOG) 9410. Proc Am Soc Clin Oncol 19:484a, 2000 (abstr 1891)
11. Curran W, Scott C, Langer C, et al: Long-term benefit is observed in a phase III comparison of sequential vs concurrent chemoradiation for patients with unresected stage III nsclc: RTOG 9410. Proc Am Soc Clin Oncol 22:621, 2003 (abstr 2499)
12. Turrisi AT 3rd, Kim K, Blum R, et al: Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 340:265-271, 1999
13. Curran WJ Jr., Choy H: Optimizing chemoradiation in locally advanced non-small-cell lung cancer. Oncology (Huntingt) 15:43-45, 2001
14. Takada M, Fukuoka M, Kawahara M, et al: Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: Results of the Japan Clinical Oncology Group Study 9104. J Clin Oncol 20:3054-3060, 2002
15. Hall EJ: The oxygen effect and reoxygenation, in Radiobiology for the Radiologist (ed 3rd). Philadelphia, PA, Lippincott, 1988, pp 137-160
16. Brizel DM, Sibley GS, Prosnitz LR, et al: Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 38:285-289, 1997
17. Fyles AW, Milosevic M, Wong R, et al: Oxygenation predicts radiation response and survival in patients with cervix cancer. Radiother Oncol 48:149-156, 1998
18. Nordsmark M, Overgaard M, Overgaard J: Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother Oncol 41:31-39, 1996
19. Stadler P, Seeker A, Feldmann HJ, et al: Influence of the hypoxic subvolume on the survival of patients with head and neck cancer. Int J Radiat Oncol Biol Phys 44:749-754, 1999
20. 2 distribution and bioreductive enzymes in human malignant brain tumors. Int J Radiat Oncol Biol Phys 29:427-431, 1994
21. De Santis M, Balducci M, Basilico L, et al: Radiotherapy, local control and survival in brain tumors. Rays 23:543-548, 1998
22. 2 tension measurements. Cancer Res 51:6098-6102, 1991
23. Gatenby RA, Kessler HB, Rosenblum JS, et al: Oxygen distribution in squamous cell carcinoma metastases and its relationship to outcome of radiation therapy. Int J Radiat Oncol Biol Phys 14:831-838, 1988
24. 2 tension measurements. Cancer Res 51:3316-3322, 1991
25. Sasai K, Ono K, Hiraoka M, et al: The effect of arterial oxygen content on the results of radiation therapy for epidermoid bronchogenic carcinoma. Int J Radiat Oncol Biol Phys 16:1477-1481, 1989
26. Werner-Wasik M, Scott C, Cox JD, et al: Recursive partitioning analysis of 1999 Radiation Therapy Oncology Group (RTOG) patients with locally-advanced non-small-cell lung cancer (LA-NSCLC): identification of five groups with different survival. Int J Radiat Oncol Biol Phys 48: 1475-1482, 2000
27. Wigren T, Oksanen H, Kellokumpu-Lehtinen P: A practical prognostic index for inoperable non-small-cell lung cancer. J Cancer Res Clin Oncol 123:259-266, 1997
28. Abraham DJ, Wireko FC, Randad RS, et al: Allosteric modifiers of hemoglobin: 2-[4-[[(3,5-disubstituted anilino)carbonyl]methyl]phenoxyl-2- methylpropionic acid derivatives that lower the oxygen affinity of hemoglobin in red cell suspensions, in whole blood, and in vivo in rats. RSR-P-92011-]. Biochemistry 31:9141-9149, 1992
29. 2 and decreases arteriolar diameter and flow in the rat cremaster muscle. RSR-P-96043-R. Microvasc Res 52:58-68, 1996
30. 2 delivery in dog muscle in situ. RSR-P-98067-D. J Appl Physiol 84:995-1002, 1998
31. Teicher BA, Ara G, Emi Y, et al: RSR13: effects on tumor oxygenation and response to therapy. RSR-P-96044-M. Drug Dev Res 38:1-11, 1996
32. Shaw E, Scott C, Suh J, et al: RSR13 plus cranial radiation therapy in patients with brain metastases: Comparison with the Radiation Therapy Oncology Group Recursive Partitioning Analysis Brain Metastases Database. J Clin Oncol 21:2364-2371, 2003
33. Kavanagh BD, Steffen RP, Chan D, et al: RSR13 modulates tumor hypoxia and HIF-1-alpha expression in H226 xenografts in vivo (abstract 1101). Int J Radiat Oncol Biol Phys 57:S321-S322, 2003
34. Teicher BA, Wong JS, Takeuchi H, et al: Allosteric effectors of hemoglobin as modulators of chemotherapy and radiation therapy in vitro and in vivo. RSR-P-98069-M. Cancer Chemother Pharmacol 42:24-30, 1998
35. Curran WJ, Jr.: Evolving chemoradiation treatment strategies for locally advanced non-small-cell lung cancer. Oncology (Huntingt) 17:7-14, 2003
36. Choy H, Curran WJ, Scott CB, et al: Preliminary report of locally advanced multimodality protocol (LAMP): ACR427: A randomized phase II study of three chemo-radiation regimens with paclitaxel, carboplatin, and thoracic radiation (TRT) for patients with locally advanced non small cell lung cancer (LA-NSCLC). Proc Am Soc Clin Oncol 21:291a, 2002 (abstr 1160)
37. Uitterhoeve AL, Belderbos JS, Koolen MG, et al: Toxicity of high-dose radiotherapy combined with daily cisplatin in non-small cell lung cancer: Results of the EORTC 08912 phase I/II study-European Organization for Research and Treatment of Cancer. Eur J Cancer 36:592-600, 2000
38. Robnett TJ, Machtay M, Vines EF, et al: Factors predicting severe radiation pneumonitis in patients receiving definitive chemoradiation for lung cancer. Int J Radiat Oncol Biol Phys 48:89-94, 2000
39. Roach M, Gandara DR, Yuo HS, et al: Radiation pneumonitis following combined modality therapy for lung cancer: Analysis of prognostic factors. J Clin Oncol 13:2606-2612, 1995
40. Kiura K, Ueoka H, Segawa Y, et al: Phase I/II study of docetaxel and cisplatin with concurrent thoracic radiation therapy for locally advanced non-small-cell lung cancer. Br J Cancer 89:795-802, 2003